The FTC Second Request signals heightened antitrust scrutiny but is common in healthcare M&A. Watch for the timing of substantial compliance and any subsequent FTC action (clearance, consent decree, or challenge). A prolonged review beyond 60-90 days would increase deal risk.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Oct 16 $4.43entry
- T+1 · 29d ago −1.13%α −1.55% · $4.38
- T+5 · 25d ago −11.74%α −11.83% · $3.91
- T+20 · 4d ago −26.86%α −25.70% · $3.24
- T+21 · todayOpen
- T+60 · in 8w Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiMedx and Sanara each received a Second Request from the FTC on October 15, 2026, extending the HSR Act waiting period for their pending merger. The Second Request delays the close by at least 30 days after substantial compliance, introducing regulatory uncertainty but not a deal-breaker. The filing confirms both parties are cooperating with the FTC, and no deal terms have changed.
Key Financial Metrics
Key Facts
- MiMedx and Sanara each received a Second Request from the FTC on October 15, 2026.
- The Second Request extends the HSR waiting period until 30 days after substantial compliance, unless extended or terminated earlier.
- Completion of the merger remains subject to HSR clearance and other closing conditions.
- The company states it continues to work constructively with the FTC.
- No changes to deal terms, consideration, or timeline beyond the Second Request were disclosed.
Financial Impact
No financial figures disclosed; the Second Request introduces a delay of at least 30 days to closing, creating uncertainty but no direct financial impact.
Risk Factors
- FTC could challenge the merger or impose conditions that alter deal economics.
- Extended HSR review could delay close beyond expectations, creating financing or operational uncertainty.
- If the deal fails to close, MiMedx may face integration costs or strategic setback.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001213900-26-110047 |
| Document: 0001213900-26-110047-index-headers.html | 0001213900-26-110047 |
| Document: 0001213900-26-110047-index.html | 0001213900-26-110047 |
| Document: 0001213900-26-110047.txt | 0001213900-26-110047 |
Track record
10 reports on MDXG
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +26.86% at T+20 after the Oct 16, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $3.21 Now $3.18 −0.93% settles Nov 20
- Oct 28, 202619d ago 8-K Bearish 6/10 No price data
- Oct 28, 202619d ago Press Release Bearish 6/10 Entry $3.97 to $3.28 Now $3.18 +19.90% ▲ +17.38% +12.65% vs SPY
- Oct 28, 202619d ago Press Release Bullish 5/10 Entry $3.97 to $3.28 Now $3.18 −19.90% ▼ −17.38% −12.65% vs SPY
- Oct 16, 20264w ago 425 Mixed 5/10 Viewing Entry $4.43 to $3.91 Now $3.18 −28.22% ▼ −11.74% −11.83% vs SPY
- Oct 16, 20264w ago 8-K Bearish 6/10 Entry $4.43 to $3.91 Now $3.18 +28.22% ▲ +11.74% +11.83% vs SPY
- Jun 2, 202624w ago Court Ruling Bullish 5/10 Entry $3.57 to $3.71 Now $3.18 −10.92% ▲ +3.92% +6.89% vs SPY
- Apr 29, 202628w ago DEFA14A Neutral 3/10 Entry $3.36 to $3.66 Now $3.18 −5.36% ▲ +8.93% +7.20% vs SPY
- Apr 22, 202629w ago Press Release Neutral 1/10 Entry $3.31 to $3.27 Now $3.18 −3.93% ▼ −1.36% −1.41% vs SPY
- Apr 16, 202630w ago 8-K Bearish 7/10 Entry $3.43 to $3.35 Now $3.18 +7.29% ▲ +2.33% +3.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers